GC Cell Collaborates with Taiwan's LucasBio to Develop Immunocyte Therapy

GC Cell (GC Cell) announced on the 22nd that it has signed a strategic cooperation agreement with Taiwan's Lucas Biomedical to develop immune cell therapies and expand the market.

Eric Tang, Chairman of Lucas Biomedical, and James Park, CEO of GCell, are taking a commemorative photo at the signing ceremony of the strategic cooperation agreement.
[Photo by GCell]

Lucas Biomedical is an advanced biotechnology company located in Taiwan. It received technology transfer from GCLTEC, a subsidiary of GC Cell, and the National Cancer Center of Japan, and is currently conducting a Phase 2 clinical trial of LuLym-T, an immune cell therapy using autologous cytokine-induced killer (CIK) T cells, as a post-operative treatment for liver cancer. In addition, it operates its own immune cell therapy production facilities and cold chain (refrigerated and frozen distribution) within Taiwan.

Through this cooperation agreement, GC Cell plans to jointly research the mechanism of action and clinical data of autologous immune cell therapies and strengthen the global recognition of T cell therapies. According to the agreement, GC Cell will provide real-world data (RWD) from domestic clinical use of its anticancer immune cell therapy Imucell-LC Injection, while Lucas Biomedical will mutually share research and clinical data of LuLym-T obtained in Taiwan and collaborate on additional process development and expansion of clinical indications in the future.

Due to the nature of the cell and gene therapy field, integrated value chain capabilities covering the entire process from research and development (R&D) to manufacturing, commercialization, and same-day distribution are extremely important. Both GC Cell and Lucas Biomedical possess such integrated capabilities. GC Cell operates its own bio-logistics solution and a cold chain system capable of same-day or next-day delivery to 5,000 hospitals and clinics nationwide, while Lucas Biomedical maximizes treatment efficiency by rapidly delivering cell therapies throughout Taiwan through its self-operated cold chain supply network.

Eric Tang, Chairman of Lucas Biomedical, stated, "In addition to clinical trials to prevent liver cancer recurrence, the implementation of Taiwan's special regenerative medicine regulations has enabled the application of LuLym-T's cell technology to various types of advanced solid cancer patients." He added, "Through this cooperation, we hope to share research results with GC Cell and help more cancer patients worldwide." James Park, CEO of GC Cell, also said, "This cooperation will be an important milestone in accelerating the development of the innovative cell therapy market in Korea and Taiwan and establishing a global network and ecosystem for cell and gene therapies." He continued, "We will do our best to accelerate the global expansion of Imucell-LC Injection and provide new treatment options to patients by continuously exchanging clinical research data and conducting joint research to build a strong and long-term partnership between the two companies."